Replies to post #381152 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

At least we know the safety board didn't see any significant safety concerns developed in the Brilacidin ph2 covid trial. The interim safety review of the ph2 trial would not have allowed Brilacidin to be advanced to the 5 day treatment if there had been any safety issues.

Now, we just wait for trial results which are expected soon.







Message in reply to:
I agree, Leo is taking the right approach. Don’t tout or pressure FDA until you know how much B rocked COVID’s butt.